Commissioner Gottlieb and the Crusade Against Opioid Abuse

FDA. Meet Scott Gottlieb, M.D., Commissioner of Food and Drugs. https://www.fda.gov/AboutFDA/CentersOffices/ucm557569.htm. Accessed May 27, 2017.

Califf RM Woodcock J Ostroff S . A proactive response to prescription opioid abuse. N Engl J Med. 2016;374:1480–1485.

CDC. Prescription opioid overdose data. https://www.cdc.gov/drugoverdose/data/overdose.html. Accessed May 27, 2017.

CDC. Fatal injury data. https://www.cdc.gov/injury/wisqars/fatal.html. Accessed May 27, 2017.

Ahmedzai SH Nauck F Bar-Sela G . A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012;26:50–60.

Cloutier C Taliano J O’Mahony W . Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. Pain Res Manag. 2013;18:75–82.

Trenkwalder C Beneš H Grote L . RELOXYN Study Group. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–1150.

Pasternak GW Pan YX . Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65:1257–1317.

Runguphan W Glenn WS O’Connor SE . Redesign of a dioxygenase in morphine biosynthesis. Chem Biol. 2012;19:674–678.

Joffe AM Hallman M Gélinas C Herr DL Puntillo K . Evaluation and treatment of pain in critically ill adults. Semin Respir Crit Care Med. 2013;34:189–200.

Rose L Haslam L Dale C Knechtel L McGillion M . Behavioral pain assessment tool for critically ill adults unable to self-report pain. Am J Crit Care. 2013;22:246–255.

Prud’homme M Cata R Jutras-Aswad D . Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse. 2015;9:33–38.

Garattini S . Evaluation of benefit-risk. Pharmacoeconomics. 2010;28:981–986.

FDA. Fact Sheet—FDA Opioids Action Plan. https://www.fda.gov/NewsEvents/Newsroom/FactSheets/ucm484714.htm. Accessed May 27, 2017.

Cheatle MD . Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015;16(suppl 1):S3–S8.

Dennis BB Bawor M Paul J . The impact of chronic pain on opioid addiction treatment: a systematic review protocol. Syst Rev. 2015;4:49.

Herzig SJ . Growing concerns regarding long-term opioid use: the hospitalization hazard. J Hosp Med. 2015;10:469–470.

Mastropietro DJ Omidian H . Abuse-deterrent formulations: part 2: commercial products and proprietary technologies. Expert Opin Pharmacother. 2015;16:305–323.

Reed K Day E Keen J Strang J . Pharmacological treatments for drug misuse and dependence. Expert Opin Pharmacother. 2015;16:325–333.

Soyka M . New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1–14.

Hero JO McMurtry C Benson J Blendon R . Discussing opioid risks with patients to reduce misuse and abuse: evidence from 2 surveys. Ann Fam Med. 2016;14:575–577.

Abraham AJ Andrews CM Yingling ME Shannon J . Geographic disparities in availability of opioid use disorder treatment for Medicaid enrollees. Health Serv Res. 2017 Mar 27. [Epub ahead of print]

Becker WC Edmond SN Cervone DJ . Evaluation of an integrated, multidisciplinary program to address unsafe use of opioids prescribed for pain. Pain Med. 2017 Mar 23. [Epub ahead of print]

Green J . Epidemiology of opioid abuse and addiction. J Emerg Nurs. 2017;43:106–113.

Grosen K Olesen AE Gram M . Predictors of opioid efficacy in patients with chronic pain: a prospective multicenter observational cohort study. PLoS One. 2017;12:e0171723.

Irwin A Jozaghi E Weir BW . Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm Reduct J. 2017;14:29.

Manchikanti L Kaye AM Knezevic NN . Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2017;20:S3–S92.

McCance-Katz EF George P Scott NA . Access to treatment for opioid use disorders: medical student preparation. Am J Addict. 2017;26:316–318.

Munzing T . Physician guide to appropriate opioid prescribing for noncancer pain. Perm J. 2017;21.16–169.

Nunes EV Gordon M Friedmann PD . Relapse to opioid use disorder after inpatient treatment: protective effect of injection naltrexone. J Subst Abuse Treat. 2017 Apr 23. [Epub ahead of print]

Sharma A Kelly SM Mitchell SG . Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19:35.

Simeone R . Doctor shopping behavior and the diversion of prescription opioids. Subst Abuse. 2017;11:1178221817696077.

Srivastava A Kahan M Nader M . Primary care management of opioid use disorders: abstinence, methadone, or buprenorphine-naloxone? Can Fam Physician. 2017;63:200–205.

FDA. Guidance for Industry. Abuse-deterrent opioids: evaluation and labeling. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf. Published April 2015. Accessed May 27, 2017.

FDA. Timeline of selected FDA activities and significant events addressing opioid misuse and abuse. https://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm338566.htm. Accessed May 27, 2017.

FDA. Drug safety priorities 2016: initiatives and innovation. https://www.fda.gov/Drugs/DrugSafety/ucm522941.htm. Accessed May 27, 2017.

Turner JR . The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial. J Clin Hypertens (Greenwich). 2012;14:810–815.

Turner JR Durham TA . Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance. Hoboken, NJ: John Wiley & Sons; 2009, chap 14.

FDA. PDUFA IV Drug Safety Five-Year Plan. https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm119244.pdf. Published December 2008. Accessed May 27, 2017.

FDA. Safe use initiative.https://www.fda.gov/Drugs/DrugSafety/SafeUseInitiative/default.htm. Accessed May 27, 2017.

Rudd RA Seth P David F Scholl L . Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–1452. [Erratum: Vol. 65, Nos. 50 & 51. MMWR Morb Mortal Wkly Rep. 2017;66:35]

Dowell D Haegerich TM Chou R . CDC Guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(No. RR-1):1–49. [Errata. Vol. 65, No. RR-1. MMWR Morb Mortal Wkly Rep. 2016;65:295]